IGBA position on identification of biological, including biosimilar medicines (2018 update of facts & figures)
Biosimilar Medicines Reading List
The impact of SPC Manufacturing Waiver on jobs, competitiveness & patient access to medicines
16th Biosimilar Medicines Conference
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
